Clearmind (CMND) broadens global AUD study, files 6-K update

Rhea-AI Filing Summary

Clearmind Medicine Inc. (NASDAQ: CMND) filed a Form 6-K for June 2025. The filing mainly furnishes a press release dated 27 June 2025 entitled “Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market.”

Key points disclosed:

• The company is expanding its global clinical trial program aimed at Alcohol Use Disorder (AUD), a market the company characterises as multibillion-dollar.
• The first four paragraphs of the press release are automatically incorporated by reference into Clearmind’s effective shelf registration statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and its equity incentive Form S-8 (File No. 333-283695).
• No financial metrics, study data, or timelines are provided in the filing itself.
• The document is informational only; it does not request shareholder action nor announce financing.

The 6-K was signed by CEO Adi Zuloff-Shani on 27 June 2025.

Insights

Biopharma Equity Analyst

TL;DR: Expansion of AUD trial hints at growth ambition; no data or funding details given—impact modest but directionally positive.

The 6-K communicates that Clearmind is enlarging its clinical footprint in Alcohol Use Disorder, a sizeable commercial opportunity should efficacy be proven. Because only the existence—not the scale, design changes, or interim results—of the expansion is disclosed, immediate valuation impact is limited. Incorporation into shelf registrations ensures any future securities offerings can reference this update, keeping capital-raising flexibility intact. Overall, the news is strategically encouraging yet lacks quantitative substantiation, so near-term share-price effect should be moderate.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of: June 2025

 

Commission file number: 001-41557

 

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

 

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒        Form 40-F ☐

 

 

 

 

 

 

CONTENTS

 

Attached hereto and incorporated herein is the Registrant’s press release issued on June 27, 2025, titled “Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market”.

 

The first four paragraphs of the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

1

 

 

EXHIBIT INDEX

 

Exhibit No.	 	 
99.1	 	Press release titled: “Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market”

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 	Clearmind Medicine, Inc.
 	(Registrant)
 	 	 
Date: June 27, 2025	By:	/s/ Adi Zuloff-Shani
 	Name: 	Adi Zuloff-Shani
 	Title:	Chief Executive Officer

 

 

3

 

FAQ

What did Clearmind Medicine (CMND) announce in its June 2025 Form 6-K?

The company disclosed a press release stating it is expanding its global clinical trial for Alcohol Use Disorder.

Does the filing include new financial results for CMND?

No. No revenue, earnings, or cash-flow figures are provided in this Form 6-K.

Why is the press release incorporated into Clearmind’s registration statements?

Incorporation lets CMND reference the trial expansion in future securities offerings without filing additional amendments.

Who signed the CMND 6-K and when?

CEO Adi Zuloff-Shani signed the report on 27 June 2025.

Is shareholder action required as a result of this filing?

No. The 6-K is informational only; it does not solicit votes or approvals.